Product Description: PHA-767491 hydrochloride is a dual Cdc7/Cdk9 inhibitor, with IC50s of 10 nM and 34 nM, respectively.
Applications: Cancer-Kinase/protease
Formula: C12H12ClN3O
Citations: Autophagy. 2021 Dec 10;1-19./Sci Rep. 2021 Mar 8;11(1):5374./Acta Pharmacol Sin. 2021 Jun 29./Nat Commun. 2024 Dec 5;15(1):10594.
References: [1]Sasi NK, et al. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300./[2]Li W, et al. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15(3):196-204./[3]Erbayraktar Z, et al. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88./[4]Montagnoli A, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357-65.
CAS Number: 942425-68-5
Molecular Weight: 249.70
Compound Purity: 99.49
Research Area: Cancer
Solubility: DMSO : 17.33 mg/mL (ultrasonic;warming)/H2O : 50 mg/mL (ultrasonic)
Target: Apoptosis;CDK
Deutsch
English
